Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19
Recruiting now
Conditions studied: Haemoglobinopathies
In brief
The COVID-19 pandemic is causing many deaths around the world, putting a strain on health services. Patients with pre-existing chronic conditions are most affected by the SARS-COV2 infection. Infectious complications are a common cause of mortality and one of the main causes of morbidity in all these diseases. The main objective of this project is the assessment of patients with thalassemia, drepanocytosis, other haemoglobinopathies and rares inherited anemias suffering from SARS-COV-2 to: 1. Obtain clinical and epidemiological data that can provide information on a possible increased vulnerability of these patients to SARS-COV-2 infection; 2. Sharing therapeutic approaches considering the lack of information about the treatment.
Key facts
- Study ID
- NCT04746066
- Run by
- Società Italiana Talassemie ed Emoglobinopatie
- People needed
- 10000
- Starts
- 2020-03-31
- Expected to finish
- 2030-12-01
- Last updated by the study team
- 2022-05-05
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with an established diagnosis of thalassemia, sickle cell disease, other haemoglobinopathies and Rare Anemia inherit with a virological diagnosis of SARS-COV-2 infection.
You may not qualify if…
- nobody
Where it is running
- E.O. Ospedali Galliera — Genova, Italy (enrolling)
- Ospedali Galliera - S.S.D. Microcitemia, anemie congenite e dismetabolismo del ferro — Genova, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.